Regimen Improves PFS in Highly Mutated Metastatic Colorectal Cancer

Regimen Improves PFS in Highly Mutated Metastatic Colorectal Cancer

(MedPage Today) -- SAN FRANCISCO -- Adding modified FOLFOX6 (oxaliplatin, leucovorin, and fluorouracil) and bevacizumab (Avastin) to atezolizumab (Tecentriq) significantly improved progression-free survival (PFS) in patients with previously untreated...

mFOLFOX/Bevacizumab/Atezolizumab Improves PFS in dMMR/MSI-H Colorectal Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

A recent study reveals that combining mFOLFOX6 and bevacizumab with atezolizumab significantly enhances progression-free survival in metastatic colorectal cancer patients.

Atezolizumab Combo Does Not Significantly Boost Survival in Ovarian Cancer

The safety profile of atezolizumab plus bevacizumab and chemotherapy in this phase 3 trial was comparable with prior reports of the agents.